## EVENT LOCATIONS

<table>
<thead>
<tr>
<th>Event</th>
<th>Venue</th>
</tr>
</thead>
<tbody>
<tr>
<td>Subspecialty Reviews</td>
<td>Grand Ballroom Lower Concourse</td>
</tr>
<tr>
<td>Brazilian Retina &amp; Vitreous Society: Brainstorm in Retina: A Clinical and Surgical Case Discussion</td>
<td>Grand Ballroom Lower Concourse</td>
</tr>
<tr>
<td>General Sessions</td>
<td>Grand Ballroom Lower Concourse</td>
</tr>
<tr>
<td>Retina Case Conference</td>
<td>Grand Ballroom Lower Concourse</td>
</tr>
<tr>
<td>Continental Breakfasts &amp; Breaks</td>
<td>Grand Foyer Lower Concourse</td>
</tr>
<tr>
<td>Lunches</td>
<td>Exhibit Hall Lower Concourse</td>
</tr>
<tr>
<td>ASRS International Member Reception</td>
<td>Willow Room Mezzanine</td>
</tr>
<tr>
<td>Welcome Reception</td>
<td>Toronto Hall of Fame Off-site</td>
</tr>
<tr>
<td>Dragon Boat Races</td>
<td>Toronto Sailing and Canoe Club Off-site shuttle transportation provided</td>
</tr>
<tr>
<td>Scientific Posters and Exhibits</td>
<td>Exhibit Hall Lower Concourse</td>
</tr>
<tr>
<td>Film Festival Kiosks</td>
<td>Vide Lobby Lower Concourse</td>
</tr>
<tr>
<td>Paper on Demand (POD) Kiosks</td>
<td>Grand Ballroom Foyer Lower Concourse</td>
</tr>
</tbody>
</table>
| Instructional Courses                      | Vide Lobby Lower Concourse  
|                                            | Grand Ballroom Lower Concourse  
|                                            | Essex Ballroom Mezzanine  
|                                            | Simcoe/Dufferin, Dominion North, Dominion South, Civic North, Civic South Second Floor |
| Gala Dinner                                | Liberty Grand off-site shuttle transportation provided |
| Preceded by reception                      | Muzik Off-site shuttle transportation provided |
| Speaker-Ready Room                         | VIP Room Concourse |
| PAT Survey Posters                         | Exhibit Hall adjacent to booth 225 |
| Young Physicians Section (YPS) Symposium and Lunch | Dominion South Second Floor |
| Women in Retina (WinR) Symposium and Lunch | Dominion South Second Floor |

---

The American Society of Retina Specialists is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

The American Society of Retina Specialists designates this live activity for a maximum of 31 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

**Disclosure Information**

In accordance with the ACCME’s Standards for Commercial Support, ASRS required all individuals controlling the content of this CME activity to disclose any relevant financial relationships with commercial interests. ASRS implemented mechanisms to manage any conflicts of interest. Please see the program booklet (our mobile meeting site) for disclosure information for all planners and teachers of this CME activity.
1:43 EDI-OCT of Intraocular Tumors: Hot Off the Press, Carol Shields, MD
1:51 Results of Pd-103 Plaque Brachytherapy for Small Choroidal Melanoma, Paul Finger, MD, FACS
1:59 Discussion
2:07 Choroidal Thickness After Treatment of Uveal Melanoma With Iodine-125 Plaque Brachytherapy, William Mieler, MD
2:15 Fundus Autofluorescence and Primary Vitreoretinal Lymphoma: Is it Clinically Useful?, Lisa Faia, MD
2:23 Retinal Vasoproliferative Tumors in Patients With Neurofibromatosis in 6 Patients, Jerry Shields, MD
2:31 Discussion
2:40-3 PM Break
3-4:45 PM Medical Case Conference
Moderators: Richard Spaide, MD and William Mieler, MD
Presenters:
Katia Taba, MD, PhD
Min Kim, MD
Peter Liggett, MD
Emil Anthony Say, MD
Mohamed Haji, MD, FRCS(C)
Shree Kurup, MD
Ron Adelman, MD, MPH
John Chen, MD, FRCS(C)
Christina Weng, MD, MBA
Bruce Saran, MD
Caroline Chee, MBBS, FRCSEd, FRCOph
Zofia Michalewska, MD, PhD
Paul Bernstein, MD, PhD
David Sarraf, MD
Colin McCannel, MD
4:45-6 PM Surgical Case Conference
Moderators: Carl Awh, MD and Kourous Rezaei, MD
Presenters:
Charles Gremillion, MD
Paul Hahn, MD, PhD
Joseph Martel, MD
Pear Pongsachareonnont, MD
Tidarat Prechanond, MD
Jay Stewart, MD
Glenn Yiu, MD, PhD
Panelists:
Nur Acar, MD
Virgilio Morales-Canton, MD
David Chow, MD, FRCS(C)
Yusuke Oshima, MD, PhD
Stanislao Rizzo, MD
Gaurav Shah, MD
7-10 PM Welcome Reception—Hockey Hall of Fame (no CME)
SUNDAY, AUGUST 25
7-8:30 AM Continental breakfast
7:30-8:30 AM Surgical Techniques I
Moderators: Carl Awh, MD and David Chow, MD, FRCS(C)
7:30 Lift and Peel 27g and 25g Vitrectomy Technique in the Management of Traction Retinal Detachments, Maria Berrocal, MD
7:38 Open-Angle Glaucoma Following Uncomplicated Pars Plana Vitrectomy. Results of the Pan-American Collaborative Study Group, Virgilio Morales-Canton, MD
7:46 Surgical Approaches to Fine-Needle Aspiration Biopsy in the Evaluation of Posterior Uveal Malignant Melanoma Treated With 125-Iodine Brachytherapy, Timothy Murray, MD, MBA
7:54 Discussion
8 Effect of Filters on Tissue Visualization in Vitreoretinal Surgery, David Chow, MD, FRCS(C)
8:08 Intraocular Lens Rescue Via a Novel Scleral Fixation Technique, Jonathan Prenner, MD
8:16 Interim Review of Surgical Development for Subretinal Administration of Human Umbilical Tissue-Derived Cells (CNTO 2476), Michael Samuel, MD
8:24 Discussion
8:30-9:28 AM Macular
Moderators: Carl Awh, MD and David Chow, MD, FRCS(C)
8:30 Optimization of Vitrectomy for Idiopathic Macular Hole, Mathew MacCumber, MD, PhD
8:34 Surgical Outcomes in Patients With Macular Pucker and Good Preoperative Visual Acuity After Vitrectomy With Membrane Peeling, Gayatri Reilly, MD
8:42 The Clinical Course of Vitreofoveal Adhesion Managed by Initial Observation, Harry Flynn, MD
8:50 Discussion
8:56 Baseline Features Predictive of Pharmacologic Vitreomacular Adhesion (VMA) Resolution and Full-Thickness Macular Hole (FTMH) Closure With Ocriplasmin, Tarek Hassan, MD
9 Characterization of Full-Thickness Macular Holes in the MIVI-TRUST Program: An Optical Coherence Tomography (OCT) Analysis of Ocriplasmin Efficacy, Peter Kaiser, MD
9:04 Ocriplasmin for the Treatment of Vitreomacular Traction: Clinical Indications and Predictors of Success, Daniel Roth, MD
9:08 Foveolar Lucency and Delayed Structural Recovery After Macular Hole Closure in the Ocriplasmin Phase III Program, Tamer Mahmoud, MD, PhD
9:12 Short-Term Efficacy and Safety of a Single Intravitreal Injection of Ocriplasmin in Patients With Symptomatic Vitreomacular Adhesion (VMA), Jacob Meyer, MD
9:16 Discussion
9:28-9:50 AM Break
11:05-11:50 AM  Genetics and Disease Symposium
Moderators: John Thompson, MD and Tarek Hassan, MD
11:05  Genetic Analysis Increases the Predictive Accuracy for Progression From Early to Advanced AMD, Lawrence Singerman, MD
11:13  Earlier Detection of Advanced AMD Due to Office-Based Genetic Testing for AMD Risk, Peter Sonkin, MD
11:21  Genotype Analysis for Single Nucleotide Polymorphisms: Profile of Eyes With Vascularized PED Due to AMD vs. Eyes Without AMD and Eyes With Drusen, Clement Chan, MD, FACS
11:29  CFH and ARMS2 Genetic Polymorphisms Predict Response to Antioxidants and Zinc in Patients With Age-Related Macular Degeneration Carl Awh, MD
11:37  Discussion

11:50 AM-1:20 PM  General Lunch; Young Physicians Section (YPS) Symposium Lunch (no CME)

1:20-2:10 PM  AMD I
Moderators: Jeffrey Heier, MD and Pravin Dugel, MD
1:20  HARBOR 2-Year Results Support Individualized Dosing in Patients With Wet Age-Related Macular Degeneration, Brandon Busbee, MD
1:28  Effect of Monthly vs PRN Ranibizumab on Patient-Reported Visual Function for Subfoveal Neovascular Age-Related Macular Degeneration Over 24 Months, Neil Bressler, MD
1:36  Anti-therapeutic Antibody Status Does Not Appear to Impact Treatment Response to Ranibizumab in the HARBOR Study, Karl Csaky, MD, PhD
1:40  Evaluation of the Presence and Extent of Geographic Atrophy Over 2 Years in the HARBOR Trial, Srinivas Sadda, MD
1:44  Ranibizumab Leads to Regression or Elimination of Choroidal Neovascular Membranes in Most Eyes With AMD: A HARBOR Subanalysis, John Kitchens, MD
1:48  Discussion
1:54  The Effect of Early, Persistent Fluid on Subsequent Visual Acuity in the VIEW 1 and VIEW 2 Studies of Neovascular AMD, Glenn Jaffe, MD
2:02  Association Between Retinal Fluid Status at Weeks 12 and 52 in Wet-AMD Patients Treated With Intravitreal Aflibercept Injection in the VIEW Studies, Seenu Hariprasad, MD
2:06  Discussion

2:10-3:30 PM  AMD 2
Moderators: Jeffrey Heier, MD and Pravin Dugel, MD
2:10  Anti-VEGF Therapy Outcomes of First and Second Eyes Utilizing Electronic Medical Records: The Future for Phase IV Trials, Adnan Tufail, MBBS, MD, FRCPhtth
2:18  Vitreous Proteomics Reveals a Biomarker Panel That Predicts the Response of Patients With Wet AMD to Treat-and-Extend Therapy, Bert Glaser, MD
2:26  Comparison of Systemic Pharmacokinetics Post-Anti-VEGF Intravitreal Injections of Ranibizumab, Bevacizumab and Aflibercept, Robert Avery, MD
2:34  VEGF Plasma Level After Intravitreal Injection of Bevacizumab, Ranibizumab and Pegaptanib in Patients With Age-Related Macular Degeneration and Diabetic Macular Edema, Gerhard Kieselbach, MD, Prof.
2:42  Discussion
2:50  Omega-3 Supplementation and VEGF Levels in Wet AMD, Flavio Rezende, MD, PhD
2:58  Lutein/Zeaxanthin and Omega-3 Fatty Acids for Age-Related Macular Degeneration. Results of the Age-Related Eye Disease Study 2 (AREDS2) Randomized Clinical Trial, Emily Chew, MD
3:06  ForeseeHome in AREDS2-Home Monitoring of AMD Patients for Neovascular AMD: Study Design, Enrollment, Baseline Characteristics and Initial Device Usage, Susan Bressler, MD
3:14  Periodontal Disease and Age-Related Macular Degeneration, Jorge Arroyo, MD, MPH
3:18  Discussion

3:30-3:50 PM  Break

3:50-5:30 PM  Inherited, Inflammatory, and Infectious Disease
Moderators: Harry Flynn, MD and Allen Ho, MD
3:50  Programed Necrosis, but Not Apoptosis, Mediates Photoreceptor Cell Loss and Inflammation in dsRNA-Induced Retinal Degeneration, Jennifer Lim, MD
3:58  Long-term Follow-up for Efficacy and Safety of Treatment of Retinitis Pigmentosa With Valproic Acid, Christine Kay, MD
4:06  Visual and Anatomic Results of the Macula Society Photodynamic Therapy (PDT) for Chronic Central Serous Chorioretinopathy (CSC) Retrospective Study, Jennifer Lim, MD
4:14  Micropulse Photocoagulation Versus Half-Dose Verteporfin Photodynamic Therapy in the Treatment of Central Serous Chorioretinopathy, Michael Koss, MD
4:22  Discussion
4:28  Suprachoroidal Drug Delivery of Triamcinolone Acetonide in Vogt-Koyanagi-Harada Disease, Michael J. Davis, MD
4:32  New Perspectives on Autoimmune Retinopathy: Cases From a National Cancer Institute Designated Cancer Center, Jennifer Spiegel, MD
4:36  Endophthalmitis Following Vitrectomy: A Prospective Nationwide UK Study, Somdutt Prasad, MS, FRCSEd, FRCPhtth, FACS
4:40  Discussion
4:46 Eliminating Antibiotic Prophylaxis for Intravitreous Injections: A Consecutive Series of 18,839 Injections by a Single Surgeon, **Abdhish Bhavsar, MD**

4:54 The Role of Topical Antibiotic Prophylaxis to Prevent Endophthalmitis After Intravitreal Injection, **Sunir Garg, MD**

5:02 Initial Presentation of Fungal Endophthalmitis Outbreak Following Intravitreal Injections of Triamcinolone Contaminated by a Compounding Pharmacy, **Kent Small, MD**

5:06 Characterization of Sterile Intraocular Inflammatory Reactions After Intravitreal Aflibercept Injection, **Deborah Chong, MD**

5:10 Sterile Intraocular Inflammation in a Cluster of Patients Receiving Intravitreal Injections of Bevacizumab Prepared From a Single Vial, **Michael Stewart, MD**

5:14 A Cluster of Sterile Inflammation Associated With Aflibercept Intravitreal Injections—An ASRS Therapeutic Surveillance Committee Report, **Paul Hahn, MD, PhD**

5:18 Discussion

5:30-6:30 PM **Scientific Posters and Exhibit Hall Reception** (no CME)

6:30-9:30 PM **Dragon Boat Races** (no CME)

---

**MONDAY, AUGUST 26**

6:30-8 AM **Continental breakfast**

7-7:25 AM **ASRS Business Meeting** (no CME)

7:25-7:30 AM **PAT Survey Presentation**

Thomas Stone, MD

7:30-9:30 AM **Retinal Detachment, Instruments/Devices I**

Moderators: **John Pollack, MD and Andrew Schachat, MD**

7:30 Management of Retinal Detachments: The European Vitreo-Retinal Society Retinal Detachment Study, **Ron Adelman, MD, MPH**

7:38 Scleral Buckling for Rhegmatogenous Retinal Detachment Using Vitrectomy-Based Visualization Systems and Chandelier Illumination, **Manish Naggal, MD, FRCS (UK)**

7:42 Intraoperative Spectral-Domain OCT During Pars Plana Vitrectomy for Macula-Involving Retinal Detachments, **Sunil Srivastava, MD**

7:46 Does Combined Phaco-vitrectomy for Rhegmatogenous Retinal Detachment (RRD) Modify the Risk of Developing Proliferative Vitreoretinopathy (PVR)? **Rubina Rahman, MBBS, FRCOpth, FRCS**

7:50 Giant Retinal Tear (GRT) Detachments: Surgical Strategies and Outcomes, **John Pitcher, MD**

7:54 Discussion

8:07 Unexplained Visual Loss After Removal of Silicone Oil: Results of the Pan-American Collaborative Retina Study Group (PACORES), **Jose Roca, MD**
11:28 Macular Development In Vivo Followed by Fluorescein Angiography and Spectral-Domain OCT in Premature Patients With Retinopathy of Prematurity (ROP), Maria Martinez-Castellanos, MD

11:36 Adult Retinopathy of Prematurity: A 35-Year Review, Joshua Robinson, MD

11:44 Discussion

11:52 Long-term Outcomes of Lens Clarity Following Lens-Sparing Vitrectomy for Retinopathy of Prematurity, Michael Trese, MD

11:56 Long-term Anatomic, Visual, and Quality-of-Life Outcomes of Lens-Sparing Vitrectomy for Stage 4 Retinopathy of Prematurity, G. Baker Hubbard, MD

12 Retinal Vascularization After Intravitreal Bevacizumab Injection for Aggressive Posterior Retinopathy of Prematurity (AP-ROP), Sjakon Tahija, MD

12:04 ROPER: Is It ROP or Is It FEVR?, Audina Berrocal, MD, FACS

12:08 Discussion

12:16 Choroidal Thickness in Patients With a History of Retinopathy of Prematurity, Wei-Chi Wu, MD, PhD

12:20 Digital Imaging to Reduce Visual Impairment in Neonates and Children, Kimberly Drenser, MD

12:24 Evolution and Treatment of Traction Retinal Detachments Associated With Severe Coats’ Disease in Children, Philip Ferrone, MD

12:28 Clinical Features and Outcomes of Rhegmatogenous Retinal Detachment in the Pediatric Population, Justin Townsend, MD

12:32 Discussion

12:40-1:45 PM General Lunch; Women in Retina (WinR) Lunch (no CME)

5-6 PM Scientific Posters and Exhibit Hall Reception (no CME)

6-7:30 PM Women in Retina (WinR) Case Conference (no CME)

7-10 PM FIT Section Speed Networking Evening (no CME)

TUESDAY, AUGUST 27

7-8 AM Continental breakfast

7:30-9:30 AM AMD 3, Diabetic Retinopathy I

Moderators: Suber Huang, MD, MBA and George Williams, MD

7:30 Pachychoroid Pigment Epitheliopathy, K. Bailey Freund, MD

7:38 Cell Therapy for AMD: Interim Results of a Phase 1 Clinical Study Evaluating the Safety and Clinical Response of Human Umbilical Tissue-Derived Cells, Allen Ho, MD

7:46 MAHALO Phase II Study: Safety, Tolerability and Activity of Lampalizumab (Anti-factor D) in Patients With Geographic Atrophy, David Williams, MD, MBA

7:54 Discussion

8:04 Smoking and Choroidal Thickness in Patients Over 65 With Placoid Drusen, Early Atrophic Age-Related Macular Degeneration, and Normals, Eric Sigler, MD

8:08 Correlation Between the Subfoveal Choroidal Thickness and the Severity or the Progression of Dry Age-Related Macular Degeneration, Young HeeYoon, MD

8:12 Discussion

8:18 Wet AMD: What Happens When You Switch Anti-VEGF Agents?

8:20 Afibercept for Exudative AMD With Persistent Fluid on Ranibizumab and/or Bevacizumab, Hyung Cho, MD

8:23 What Happens When You Switch Wet-AMD Patients to Afibercept? Theodore Leng, MD, MS

8:26 Response of Afibercept in Patients With Neovascular AMD and Persistent Fluid on OCT, Ashish Sharma, MD, FACS

8:29 Longer-term Results of Afibercept in Cases of Neovascular AMD Incompletely Responsive to Other Anti-VEGF Agents, Franco Recchia, MD

8:32 Long-term Follow-up on the Use of Afibercept for the Treatment of Refractory Neovascular Age-Related Macular Degeneration, Sara Haug, MD, PhD

8:35 Worsening of Macular Edema After Afibercept Injection for Exudative ARMD in Eyes Previously Well Controlled With Ranibizumab, Eric Nudleman, MD, PhD

8:38 Discussion

8:48 Intravitreal Ranibizumab Modifies the Natural History of Diabetic Retinopathy: 36-Month Data From the RISE and RIDE Phase III Trials, W. Lloyd Clark, MD

8:56 Effect of Ranibizumab Injections for Diabetic Macular Edema on Risk of Sustained IOP Elevation or Initiation of Ocular Anti-hypertensive Drugs, Suber Huang, MD, MBA

9:04 Randomized Clinical Trial Evaluating Intravitreal Ranibizumab or Saline for Vitreous Hemorrhage From Proliferative Diabetic Retinopathy, Victor Gonzalez, MD

9:12 Discussion

9:20 Evaluation of Nepafenac 0.1% in the Prevention of Macular Edema (ME) Following Cataract Surgery in Patients with Diabetic Retinopathy, Rishi Singh, MD

9:28 Discussion

9:30-10 AM Break

10-11 AM Retinal Vascular Disease

Moderators: David Williams, MD, MBA and Timothy Murray, MD, MBA

10 Effect of Alternate Ranibizumab (RBZ) Dosing Regimens on Visual and Anatomic Outcomes in Patients with Retinal Vein Occlusion (RVO) — The SHORE Study, Dennis Marcus, MD

10:08 Systemic Safety Profile of Intravitreal Ranibizumab in Wet AMD, RVO, and DME: A Meta-Analysis of 14 Phase II/III Clinical Trials, Baruch Kuppermann, MD, PhD

10:16 Factors Associated With the Number of Intravitreal Afibercept Injections (IAI) During the PRN Phase of CRVO Studies, David Boyer, MD

10:24 Discussion

10:32 Ranibizumab and Afibercept for the Treatment of Retinal Vein Occlusion (RVO): A Cross-Trial Comparison, Pravin Dugel, MD
10:36 Dexamethasone Implant Anterior-Chamber Migration: Risk Factors, Complications, and Management Strategies, Rahul Khurana, MD

10:40 Retrospective Study of Two or More Dexamethasone Intravitreal Implant Injections for Treatment of Macular Edema Secondary to Retinal Vein Occlusion, Shree Kurup, MD

10:44 Safety and Feasibility of a Biodegradable Implant of Dexamethasone (DDS-25 Gauge) for Macular Edema Associated With Retinal Vein Occlusion: A Phase I/I Clinical Trial, Rodrigo Jorge, MD

10:48 Does Addition of Laser Increase Efficacy in Retinal Vein Occlusion Eyes Treated With Simultaneous Bevacizumab and Dexamethasone Intravitreal Implant? Alay Banker, MD

10:52 Discussion

11 AM-12:27 PM Instruments/Devices II, Surgical Techniques II

Moderators: David Williams, MD, MBA and Timothy Murray, MD, MBA

11:06 Expanded Criteria for Pneumatic Retinopexy and Potential Cost Savings, Darin Goldman, MD

11:08 Assessment of a New Light-Emitting Diode-Based Light Source for Vitreotomy Surgery, Colin McCannel, MD

11:16 New Shapes for Vitreous Cutter Blades: A Particle Image Velocimetry Study, Tommaso Rossi, MD, EBOD

11:24 Discussion

11:34 Combined Pars Plana Vitrectomy and Glaucoma Drainage Device Surgery in Complex Pediatric Glaucoma: Outcomes and Complications, Prithvi Mruthyunjaya, MD

11:38 Optic Pit Maculopathy: Surgical Technique and Long-term Follow-up. A Multicenter Milan Study, Fabio Patelli, MD

11:42 Intramacular, Microdissection for Recurrent Macular Holes With Cystic Edges, Nabil Jabbour, MD, FACS

11:46 Retinal and Intravitreal Temperature During Vitreous Surgery, Gabriela Lopezcarasa Hernandez, MD

11:50 Vitreectomy With 25-Gauge and Incomplete Drainage of Subretinal Fluid for the Treatment of Primary Rhegmatogenous Retinal Detachment, Stratos Gotzaridis, MBBS, MD

11:54 Discussion

12:04 Experimental Comparison of Peripheral Vitreous Incarceration Using Valved and Non-valved Cannula in a Cadaveric Animal Eye Model, Martin Charles, MD

12:08 Iatrogenic Retinal Breaks in 25-Gauge Vitrectomy Under Air (Airbag-Vitrectomy) Compared With the Standard 25-Gauge System for Macular Diseases, Cesare Mariotti, MD

12:12 Collateral Damage, Kourosh Rezaei, MD

12:16 One-Year Results of the Prospective Retinal and Optic Nerve Vitrectomy Evaluation (PROVE) Study: A Controlled Clinical Trial, Rohan Shah, MD

12:20 Discussion

12:27-1:30 PM Lunch

1:30-5:30 PM Instructional Courses

1:30-2:20 Duke Surgery Rounds: Deconstructing PPV...

Essex

Faculty: Tamer H. Mahmoud, MD, PhD; Prithvi Mruthyunjaya, MD; Glenn J. Jaffe, MD; Carl C. Awh, MD; Dean Elliott, MD; J. Michael Jumper, MD

1:30-2:20 EMR Implementation and Optimization for Retina

Second Floor

Faculty: Sanjay Logani, MD, MBA

1:30-2:20 Endoscopic Vitrectomy in Adult and Pediatric Vitreoretinal Diseases,

Second Floor

S. Wong, MBBS, FRCSEd(ophth), MRCophth

Faculty: Thomas C. Lee, MD; Allen C. Ho, MD; Victor Hugo Gonzalez, MD; Jeffrey S. Heier, MD

1:30-2:20 ICG Imaging for the Diagnosis and Management of Exudative Age-Related Macular Degeneration

Second Floor

Faculty: Mark Nelson, MD, MBA

1:30-2:20 Surgical Management of Complicated Retinal Detachments, Jay Chhablani, MD

Second Floor

Faculty: Raja Narayanan, MD; Hemanth Murthy, MBBS, MD; Manish Nagpal, MD, FRCS (UK); Alay S. Banker, MD

1:30-3:00 ‘First 20 Dates With Internal Limiting Membrane (ILM)’ Tips on Macular Surgery Techniques for Beginners, Malhar Soni, DO, MS, DNB, FRCS

Second Floor

Faculty: Pravin U. Dugel, MD; Gopal Lingam, MS, FRCS; Steve T. Charles, MD

2:30-3:00 Subthreshold Laser Treatment of Diabetic Macular Edema: Methods to Maximize Structural and Visual Outcomes, Jeffrey Luttrull, MD

Second Floor

Faculty: Stephen H. Sinclair, MD; Edoardo Midena, MD, PhD, FARVO, FEBO

2:30-3:00 Vitreomacular Interface Pathology: OCT Interpretations, Wai-Ching Lam, MD, FRCS(C)

Second Floor

Faculty: Emmanouil Mavrikakis, MD, PhD; Varun Chaudhary, MD; Shao Onn Yong, MD, FRCSE; Rajeev H Muni, MD, MSC, FRCSC,

2:30-3:00 Powerplay: Vitreoretinal Surgery in Inflamed Eyes, Thomas Albini, MD

Second Floor

Faculty: Steven Yeh, MD; Efrem D. Mandelcorn, MD; Thomas C. Lee, MD; Allen C. Ho, MD; S. Wong, MBBS, FRCSEd, MRCOphth

2:30-3:00 Intraocular Tumors and Pseudotumors. Rapid-Fire Cases and Clinical Pearls, Jerry Shields, MD

Second Floor

Faculty: Carol L. Shields, MD

2:30-3:00 Anterior-Segment Microsurgery for the Vitreoretinal Surgeon: Techniques, Tools, and Tips, Yannek Leiderman, MD, PhD

Second Floor

Faculty: Maria H. Berrocal, MD; Netan Choudhry, MD, FRCS(C); Jonathan L. Prenner, MD
### WEDNESDAY, AUGUST 28

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
<tbody>
<tr>
<td>7:30-8:30 AM</td>
<td><strong>Continental breakfast</strong></td>
</tr>
<tr>
<td>8:21 AM</td>
<td><strong>Surgical Techniques III</strong></td>
</tr>
<tr>
<td></td>
<td>Moderators: Donald D’Amico, MD and Virgilio Morales-Canton, MD</td>
</tr>
<tr>
<td>8</td>
<td>Lutein: A New Dye for Chromovitrectomy, Mauricio Maia, MD, PhD</td>
</tr>
<tr>
<td>8:04</td>
<td>Vitrectomy for Macular Hole Retinal Detachment (MHDR) in High Myopia,Stanislaw Rizzo, MD</td>
</tr>
<tr>
<td>8:08</td>
<td>25-Gauge Vitrectomy for Macular Holes With and Without Retinal Detachment in Highly Myopic Eyes, Francesco Boscia, MD</td>
</tr>
<tr>
<td>8:12</td>
<td>Inverted Internal Limiting Membrane Flap Technique in Macular Hole Associated With Pathological Myopia, Jerzy Nawrocki, MD, PhD</td>
</tr>
<tr>
<td>8:16</td>
<td>Discussion</td>
</tr>
<tr>
<td>8:21-9:46 AM</td>
<td><strong>Imaging</strong></td>
</tr>
<tr>
<td></td>
<td>Moderators: Donald D’Amico, MD and Virgilio Morales-Canton, MD</td>
</tr>
<tr>
<td>8:21</td>
<td>Clinical Feasibility and Utility of Ultra Wide-field Indocyanine Green (ICG) Angiography, Szilard Kiss, MD</td>
</tr>
<tr>
<td>8:29</td>
<td>Adaptive Optics Scanning Laser Ophthalmoscope Fluorescein Angiography (AO SLO FA) and Motion Contrast Imaging of Retinal Microaneurysms, Richard Rosen, MD</td>
</tr>
<tr>
<td>8:37</td>
<td>Discussion</td>
</tr>
<tr>
<td>8:43</td>
<td>Diurnal Variation of Macular Choroidal Volume in Healthy Volunteers, Lihteh Wu, MD</td>
</tr>
<tr>
<td>8:51</td>
<td>Two-Year Macular Volume Change of the Retinal Pigment Epithelium and Drusen Complex (RPEDC) in Intermediate AMD by SD-OCT Semi-Automated Segmentation, Thomas Hwang, MD</td>
</tr>
<tr>
<td>8:59</td>
<td>Discussion</td>
</tr>
<tr>
<td>9:05</td>
<td>Correlation of Precise Area of Peripheral Non-perfusion With the Ischemic Index in Retinal Vein Occlusion, Michael Singer, MD</td>
</tr>
<tr>
<td>9:09</td>
<td>Lamina Suprachoroidea and Suprachoroidal Space Delineating the Outer Margin of the Choroid in Swept-Source OCT, Zofia Michalewska, MD, PhD</td>
</tr>
<tr>
<td>9:13</td>
<td>Intraoptic Nerve Head and Retina Silicone Oil Microspherules: OCT (Swept Source) and Adaptive Optics Reflectance Imaging, Yale Fisher, MD</td>
</tr>
<tr>
<td>9:17</td>
<td>Can Retro-illuminated Infrared Choroidal Imaging Distinguish Polypoidal Choroidal Vasculopathy From Neovascular Age-Related Macular Degeneration? Christina Leung, MD, FRCS(C)</td>
</tr>
<tr>
<td>9:21</td>
<td>Discussion</td>
</tr>
<tr>
<td>9:28</td>
<td>SD-OCT and Fundus Autofluorescence Findings of Acute Sphilitic Posterior Placoid Chorioretinopathy: An International Perspective, David Sarraf, MD</td>
</tr>
<tr>
<td>9:32</td>
<td>Evaluation of a Combination Non-mydriatic Digital Fundus Camera With Spectral Domain OCT in Telemedicine for the Screening of Diabetic Retinopathy, John Wroblewski, MD</td>
</tr>
</tbody>
</table>
Enhanced Depth Imaging Optical Coherence Tomography in Patients With Different Phase Behçet’s Disease, Gursel Yilmaz, MD

Discussion

9:46-10:10 AM Break

10:10-10:40 AM Global Trends in Retina

Moderators: Lihteh Wu, MD and Francesco Boscia, MD

Moderator:
Malhar Soni, DO, MS, DNB, FRCS
Europe & Asia: ‘Retina Practice Trends’

Panelists:
Martin Charles, MD South America
Ehab El Rayes, MD, PhD Middle East & Africa
Kourous Rezaei, MD North America: ASRS PAT Survey
Stanislas Rizzo, MD Europe
P. Mahesh Shanmugam, DO, FRCSEd, PhD, FAICO(VR) Asia: ‘Retina Practice Trends’

10:40-11:50 Diabetic Retinopathy II

Moderators: Lihteh Wu, MD and Francesco Boscia, MD

10:40 Why the 0.3 mg Dose of Ranibizumab Was Recommended for the Treatment of Diabetic Macular Edema, Donald D’Amico, MD
10:48 Residual Edema Evaluation With 0.5 mg and 2.0 mg Ranibizumab Formulations (REEF Study), Dilsher Dhoot, MD
10:56 Discussion

11:02 A Prospective Study of Anterior-Chamber Cytokine Levels and Their Association With Disease Severity in Diabetic Macular Edema, David Wong, MD, MD, FRCS(C)
11:10 Anterior Chamber Cytokine Level Changes in Diabetic Macular Edema After Treatment With Intravitreal Ranibizumab, Rajeev Muni, MD, MSC, FRCS(C)
11:18 The Role of Macular Ischemia in Treatment-Naive Patients With Diabetic Macular Edema Treated With Intravitreal Ranibizumab Only, Andreas Ebnete, MD, PhD
11:22 A 12-Month, Masked, Randomized Controlled Study to Assess Efficacy of Dexamethasone Intravitreal Implant and Bevacizumab Compared With Bevacizumab Alone for Diabetic Macular Edema, Raj Maturi, MD
11:26 Discussion

11:36 Safety of Transfoveal Subthreshold Diode Micropulse Laser (TF SDM) for Intrafoveal Diabetic Macular Edema (IF DME) in Eyes With Good Visual Acuity, Jeffrey Luttrull, MD
11:40 Combination of Anti-angiogenic Therapy and Navigated Laser for the Treatment of Diabetic Macular Edema (DME): 12-Month Results, Igor Kozak, MD, PhD
11:44 Discussion